Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Eli Lilly and Company (LLY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 90,353,328
  • Shares Outstanding, K 1,103,350
  • Annual Sales, $ 21,222 M
  • Annual Income, $ 2,738 M
  • 36-Month Beta 0.34
  • Price/Sales 4.26
  • Price/Cash Flow 17.29
  • Price/Book 6.42

Price Performance

See More
Period Period Low Period High Performance
1-Month
79.88 +4.43%
on 04/19/17
86.72 -3.81%
on 04/05/17
-0.76 (-0.90%)
since 03/24/17
3-Month
74.00 +12.73%
on 01/31/17
86.72 -3.81%
on 04/05/17
+8.57 (+11.45%)
since 01/24/17
52-Week
64.18 +29.98%
on 11/23/16
86.72 -3.81%
on 04/05/17
+5.59 (+7.18%)
since 04/22/16

Most Recent Stories

More News
Research and Markets - Global Diabetic Therapeutic Market to Grow at a CAGR of 7.55%, 2017-2021 With AstraZeneca, Eli Lilly, Merck, Novo Nordisk and Sanofi Dominating

DUBLIN, April 24, 2017 /PRNewswire/ --

NVO : 36.54 (+1.84%)
MRK : 62.14 (+0.40%)
LLY : 83.42 (+1.87%)
What's in Store for Vertex (VRTX) this Earnings Season?

Vertex Pharmaceuticals, Inc. (VRTX) is scheduled to report first-quarter 2017 results on Apr 27, after the market closes.

RARE : 61.31 (+1.22%)
PTI : 5.48 (-4.53%)
LLY : 83.42 (+1.87%)
VRTX : 117.66 (+0.82%)
Global Biopharmaceutical Manufacturing Market Report 2017-2021: Key Vendors are Pfizer, Roche, Amgen, Novo Nordisk, AbbVie, Sanofi, Eli Lilly & Merck - Research and Markets

Research and Markets has announced the addition of the "Global Biopharmaceutical Manufacturing Market Report 2017-2021" report to their offering.

NVO : 36.54 (+1.84%)
MRK : 62.14 (+0.40%)
LLY : 83.42 (+1.87%)
3 Key Factors to Look Out for in Biogen's Q1 Results

With Biogen (BIIB) set to report Q1 results tomorrow, here is a look at 3 key factors investors will be focused on apart from earnings and revenue.

MRK : 62.14 (+0.40%)
LLY : 83.42 (+1.87%)
BMY : 53.55 (+0.13%)
BIIB : 276.86 (+1.44%)
Why Eli Lilly (LLY) Might Surprise This Earnings Season

Eli Lilly (LLY) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.

LLY : 83.42 (+1.87%)
S&P Global (SPGI) to Post Q1 Earnings: A Beat in the Cards?

S&P Global, Inc. (SPGI) is slated to report first-quarter 2017 results on Apr 25, before the markets open.

LMT : 276.21 (+1.14%)
KO : 43.28 (+0.49%)
LLY : 83.42 (+1.87%)
SPGI : 133.90 (+1.81%)
TransUnion (TRU) Q1 Earnings: What's in Store this Time?

TransUnion (TRU) is scheduled to release first-quarter 2017 results before the market opens on Apr 25.

LMT : 276.21 (+1.14%)
KO : 43.28 (+0.49%)
TRU : 39.87 (+1.55%)
LLY : 83.42 (+1.87%)
Eli Lilly (LLY) Up 8.1% Since Earnings Report: Can It Continue?

Eli Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

LLY : 83.42 (+1.87%)
Lilly Announces Phase 3 MONARCH 3 Breast Cancer Study of Abemaciclib Demonstrated Superior Progression-Free Survival at Interim Analysis

Eli Lilly and Company (NYSE: LLY) today announced that following a pre-planned interim analysis for MONARCH 3, the trial met its primary endpoint of demonstrating statistically significant improvement...

LLY : 83.42 (+1.87%)
Drug Stocks Q1 Earnings Releases on Apr 25: LLY, BIIB, NVS

As the Q1 earnings season gets in full swing this week, we believe this quarter is on track to see the highest growth in almost three years.

LLY : 83.42 (+1.87%)
NVS : 74.61 (+1.65%)
BIIB : 276.86 (+1.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Eli Lilly and Company discovers, develops, manufactures, and sells products in one significant business segment -pharmaceutical products. The company directs its research efforts primarily toward the search for products to diagnose, prevent and treat human diseases. The company also conducts research...

See More

Support & Resistance

2nd Resistance Point 84.30
1st Resistance Point 83.86
Last Price 83.42
1st Support Level 82.85
2nd Support Level 82.28

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.